Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




HPV-Positive Head and Neck Cancer Has Better Response to Treatment
Link ID 3277
Title HPV-Positive Head and Neck Cancer Has Better Response to Treatment
Url http://www.medscape.com/viewarticle/570211?src=rss
Description Tumors positive for human papillomavirus (HPV) have a better response to therapy, leading to significantly better survival than HPV-negative cancers. Medscape Medical News
Category Articles > Hematology-Oncology
Keywords
Date Feb 15, 2008
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Hematology-Oncology
1. ESAs Should Continue to be Used for Anemia in Cancer Patients, Says FDA Advisory Committee
  Erythropoiesis-stimulating agents should continue to have an oncology indication, even though questions about their safety remain. Medscape Medical News
Category:   Articles > Hematology-Oncology


2. Latest FDA Labeling Changes for Erythropoiesis-Stimulating Agents
  ESAs are no longer indicated for use in cancer patients for chemotherapy-induced anemia if the intent of chemotherapy is to cure the patient. Medscape Medical News
Category:   Articles > Hematology-Oncology


3. Video Highlights From the American Society of Clinical Oncology 44th Annual Meeting
  Research that will affect clinical practice includes a study showing that zoledronic acid reduces relapse in early breast cancer and KRAS mutations predict which patients will respond to cetuximab. Medscape Medical News
Category:   Articles > Hematology-Oncology


4. Zoledronic Acid-Thalidomide Combination Does Not Increase Renal Risk
  Maintenance therapy with zoledronic acid and thalidomide in patients with multiple myeloma does not increase the risk of renal impairment, according to a report posted on March 31st by BMC Clinical Pharmacology. Reuters Health Information
Category:   Articles > Hematology-Oncology


5. Methotrexate May Cure up to 20% of Patients With Rare Brain Tumor
  New research shows that high-dose methotrexate is the most effective drug for primary central nervous system lymphoma, with up to 20% of patients achieving a long-term remission with methotrexate alone. Medscape Medical News
Category:   Articles > Hematology-Oncology




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS